1. Home
  2. PUMP vs CTMX Comparison

PUMP vs CTMX Comparison

Compare PUMP & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProPetro Holding Corp.

PUMP

ProPetro Holding Corp.

HOLD

Current Price

$16.87

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.76

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUMP
CTMX
Founded
2007
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
977.1M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
PUMP
CTMX
Price
$16.87
$3.76
Analyst Decision
Buy
Strong Buy
Analyst Count
7
10
Target Price
$14.14
$12.10
AVG Volume (30 Days)
5.5M
2.8M
Earning Date
04-30-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
100.76
N/A
EPS
N/A
N/A
Revenue
$1,269,158,000.00
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$15.61
$7.61
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$4.51
$1.72
52 Week High
$18.50
$8.21

Technical Indicators

Market Signals
Indicator
PUMP
CTMX
Relative Strength Index (RSI) 52.47 39.49
Support Level $14.90 $3.39
Resistance Level N/A $3.91
Average True Range (ATR) 0.89 0.20
MACD -0.04 0.00
Stochastic Oscillator 50.24 39.76

Price Performance

Historical Comparison
PUMP
CTMX

About PUMP ProPetro Holding Corp.

ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: